The patient with colitis (received INCAGN01949 at 350 mg) experienced a grade ≥3 immune-related AE on day 7, which met the definition for a DLT; this patient had received avelumab (anti-PD-L1) approximately 2 months prior to receiving the first dose of INCAGN01949. Here, CD274 is linked to colitis.